var data={"title":"Digoxin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Digoxin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6030?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=digoxin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Digoxin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=digoxin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Digoxin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160142\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Digitek;</li>\n      <li>Digox;</li>\n      <li>Lanoxin;</li>\n      <li>Lanoxin Pediatric</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160143\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Digoxin;</li>\n      <li>Digoxin Injection CSD;</li>\n      <li>Lanoxin;</li>\n      <li>Pediatric Digoxin CSD;</li>\n      <li>PMS-Digoxin;</li>\n      <li>Toloxin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160189\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiarrhythmic Agent, Miscellaneous;</li>\n      <li>\n        Cardiac Glycoside</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160147\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> When changing from oral (tablets or liquid) or IM to IV therapy, dosage should be reduced by 20% to 25%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation (rate control) (off-label dose):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Total digitalizing dose (TDD):</i> IV: 8 to 12 <b>mcg</b>/kg; administer half of TDD over 5 minutes with the remaining portion as 25% fractions at 4 to 8 hour intervals (ACLS [Neumar, 2010]) <b>or</b> may administer 0.25 mg with repeat dosing to a maximum of 1.5 mg over 24 hours followed by an oral maintenance regimen (AHA/ACC/HRS [January, 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance:</i> Oral: 0.125 to 0.25 mg once daily (AHA/ACC/HRS [January, 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart failure:</b> Daily maintenance dose (<b>Note:</b> Loading dose not recommended): Oral: 0.125 to 0.25 mg once daily; higher daily doses (eg, 0.375 to 0.5 mg daily) are rarely necessary. If patient is &gt;70 years of age, has impaired renal function, or has a low lean body mass, low doses (eg, 0.125 mg daily or every other day) should be used initially (ACCF/AHA [Yancy, 2013]). <b>Note:</b> IV digoxin may be used to control ventricular response in patients with atrial fibrillation and heart failure with reduced ejection fraction (HFrEF) who do not have an accessory pathway or pre-excitation syndrome (AHA/ACC/HRS [January, 2014]). The addition of a beta-blocker to digoxin is usually more effective in controlling ventricular response, particularly during exercise (ACCF/AHA [Yancy, 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Supraventricular tachycardia (rate control) (off-label use; </b>\n      <b>ACC/AHA/HRS [Page 2015]</b>\n      <b>):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial:</i> Total digitalizing dose:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 0.5 mg loading dose, with additional 0.125 to 0.25 mg doses administered at 6- to 8-hour intervals until evidence of adequate effect (maximum total dose: 8 to 12 <b>mcg</b>/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.25 to 0.5 mg bolus; may repeat 0.25 mg bolus, up to maximum of 1 mg (or 8 to 12 <b>mcg</b>/kg) over 24 hours given at 6- to 8-hour intervals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance dose: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 0.125 to 0.25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 2.4 to 3.6 <b>mcg/</b>kg once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160169\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=digoxin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Digoxin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Atrial dysrhythmias (rate control), HF:</b> When changing from oral (tablets or liquid) or IM to IV therapy, dosage should be reduced by 20% to 25%. See table. </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Dosage Recommendations for Digoxin<sup>1</sup></caption>\n      <col align=\"left\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th colspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Total Digitalizing Dose<sup>2,3</sup></p>\n            <p style=\"text-indent:0em;\"> (mcg/kg)</p></th>\n          <th colspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Daily Maintenance Dose<sup>3,4</sup></p>\n            <p style=\"text-indent:0em;\"> (mcg/kg)</p></th></tr>\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Oral</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">IV or IM<sup>5</sup></p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Oral</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">IV or IM<sup>5</sup></p></th></tr></thead>\n      <tfoot valign=\"top\">\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>\n              <b>Heart failure:</b> A lower serum digoxin concentration may be adequate to treat heart failure (compared to cardiac arrhythmias); consider doses at the lower end of the recommended range for treatment of heart failure; a digitalizing dose (loading dose) may not be necessary when treating heart failure (Ross, 2001).</p></td></tr>\n        <tr>\n          <td colspan=\"5\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>2</sup>\n              <b>Do not give full total digitalizing dose (TDD) at once.</b> Give one-half of the total digitalizing dose (TDD) in the initial dose, then give one-quarter of the TDD in each of two subsequent doses at 6- to 8-hour intervals. Obtain ECG 6 hours after each dose to assess potential toxicity.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>3</sup>Based on lean body weight and normal renal function for age. Decrease dose in patients with decreased renal function; digitalizing dose often not recommended in infants and children.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>4</sup>Divided every 12 hours in infants and children &lt;10 years of age. Given once daily to children &gt;10 years of age and adults.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>5</sup>IM not preferred due to severe injection site pain. If IM route is necessary, administer as deep injection followed by massage of injection site.</p></td></tr></tfoot>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Preterm infant</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20-30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15-25</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5-7.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4-6</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Full-term infant</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25-35</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20-30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6-10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5-8</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">1 mo - 2 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">35-60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30-50</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10-15</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5-12</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">2-5 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30-40</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25-35</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5-10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6-9</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">5-10 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20-35</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15-30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5-10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4-8</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">&gt;10 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10-15</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8-12</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5-5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160148\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Dose is based on assessment of lean body mass and renal function. Elderly patients with low lean body mass may experience higher digoxin concentrations due to reduced volume of distribution (Cheng, 2010). Decrease dose in patients with decreased renal function (see Dosing in Renal Impairment).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Atrial fibrillation:</b>Avoid as first-line therapy; if used, do not exceed 0.125 mg/day in patients &ge;65 years (Beers Criteria [AGS 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Heart failure:</b> If patient is &gt;70 years of age, low doses (eg, 0.125 mg daily or every other day) should be used (ACCF/AHA [Yancy, 2013]). Avoid as first-line therapy; if used, do not exceed 0.125 mg/day in patients &ge;65 years (Beers Criteria [AGS 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160149\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Loading dose: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling, however, 50% to 70% of a digoxin dose is excreted unchanged in the urine. The following adjustments have been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ESRD: If loading dose necessary, reduce dose by 50% (Aronoff, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acute renal failure: Based on expert opinion, if patient in acute renal failure requires ventricular rate control (eg, in atrial fibrillation), consider alternative therapy. If loading digoxin becomes necessary, patient volume of distribution may be increased and reduction in loading dose may not be necessary; however, maintenance dosing will require adjustment as long as renal failure persists. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Manufacturer&rsquo;s labeling: Dosage reductions and close monitoring recommended; see product labeling for specific dosage recommendations based on CrCl.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternate dosing (Golightly, 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR 10 to 50 mL/minute: 0.0625 mg every 24 to 36 hours (25% to 75% of the usual dose every 24 to 36 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR &lt;10 mL/minute: 0.0625 mg every 48 hours (10% to 25% of the usual dose every 48 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Hemodialysis: Nondialyzable (due to extensive binding to skeletal muscle and myocardium): 0.0625 mg every 48 hours (10% to 25% of the usual dose every 48 hours). No supplemental dose necessary (Mooradian, 1988).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CAPD: 0.0625 mg every 48 hours (10% to 25% of the usual dose every 48 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Continuous renal replacement therapy (CRRT): 0.0625 mg every 48 hours (10% to 25% of the usual dose every 48 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Heart failure: Initial maintenance dose (Bauman, 2006; Jusko, 1974; Koup, 1975):  <b>Note: </b>The following suggested dosing recommendations are intended to achieve a target digoxin concentration of 0.7 ng/mL. Renal function estimated using Cockcroft-Gault formula.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &gt;120 mL/minute: 0.25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 80 to 120 mL/minute: Alternate between doses of 0.25 mg and 0.125 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 30 to 80 mL/minute: 0.125 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &lt;30 mL/minute: 0.125 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> A contemporary digoxin dosing nomogram using creatinine clearance and ideal body weight or height has been published for determining the initial maintenance dose in patients with heart failure to achieve a target digoxin concentration of 0.7 ng/mL (Bauman, 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Loading dose: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, 50% to 70% of a digoxin dose is excreted unchanged in the urine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maintenance dose: Dosage reductions and close monitoring recommended; see product labeling for specific dosage recommendations based on CrCl.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15796078\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160116\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lanoxin: 0.25 mg/mL (2 mL) [contains alcohol, usp, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lanoxin Pediatric: 0.1 mg/mL (1 mL) [contains alcohol, usp, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg/mL (1 mL [DSC], 2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05 mg/mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Digitek: 125 mcg [scored; contains fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Digitek: 250 mcg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Digox: 125 mcg [scored; contains fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Digox: 250 mcg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lanoxin: 62.5 mcg [contains corn starch, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lanoxin: 125 mcg [scored; contains fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lanoxin: 187.5 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lanoxin: 250 mcg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mcg, 250 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160101\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950035\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo-Digoxin: 62.5 mcg, 125 mcg, 250 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F803126\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: IV route preferred. If IM injection necessary, administer by deep injection followed by massage at the injection site. Inject no more than 2 mL per injection site. May cause intense pain.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: May be administered undiluted or diluted. Inject slowly over &ge;5 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vesicant; ensure proper needle or catheter placement prior to and during administration; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b> Extravasation management:</b> If extravasation occurs, stop IV administration immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160120\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation:</b> Control of ventricular response rate in adults with chronic atrial fibrillation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart failure:</b> Treatment of mild-to-moderate (or stage C as recommended by the ACCF/AHA) heart failure (HF) in adults; to increase myocardial contractility in pediatric patients with heart failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In treatment of atrial fibrillation (AF), use is not considered first-line in patients with AF; digoxin may be considered for rate control in patients with heart failure with reduced ejection fraction (HFrEF) without pre-excitation or in sedentary patients (AHA/ACC/HRS [January 2014]). In the treatment of heart failure, digoxin should be considered for use only in HF with reduced ejection fraction (HFrEF) when symptoms remain despite guideline-directed medical therapy or as initial therapy in patients with severe symptoms yet to respond to guideline-directed medical therapy (ACCF/AHA [Yancy 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725522\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Fetal tachycardia; Supraventricular tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160198\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-left:2em;\">Digoxin may be confused with Desoxyn, doxepin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lanoxin may be confused with Lasix, levothyroxine, Levoxyl, Levsinex, Lomotil, Mefoxin, naloxone, Xanax</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Digoxin is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older as first-line therapy for atrial fibrillation (due to more effective alternatives and potential for increased mortality) or as first-line therapy for heart failure (due to potential for increased mortality, questionable effects on risk of hospitalization, and lack of additional benefit when higher doses are used despite the increased risk of toxicity). If used, avoid doses greater than 0.125 mg/day due to decreased renal clearance of digoxin which may result in increased risk of toxic effects; further dose reductions may be warranted in patients with Stage 4 or 5 chronic kidney disease (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Digoxin (at doses greater than 0.125 mg/day) is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lanoxin [US, Canada, and multiple international markets] may be confused with Limoxin brand name for ambroxol [Indonesia] and amoxicillin [Mexico]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160108\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidence not always reported. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Accelerated junctional rhythm, asystole, atrial tachycardia with or without block, AV dissociation, first-, second- (Wenckebach), or third-degree heart block, facial edema, PR prolongation, PVCs (especially bigeminy or trigeminy), ST segment depression, ventricular tachycardia or ventricular fibrillation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness (6%), mental disturbances (5%), headache (4%), apathy, anxiety, confusion, delirium, depression, fever, hallucinations </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Rash (erythematous, maculopapular [most common], papular, scarlatiniform, vesicular or bullous), pruritus, urticaria, angioneurotic edema </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea (4%), vomiting (2%), diarrhea (4%), abdominal pain, anorexia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ocular: Visual disturbances (blurred or yellow vision)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Laryngeal edema </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports (limited to important or life-threatening): Asymmetric chorea, gynecomastia, thrombocytopenia, palpitation, intestinal ischemia, hemorrhagic necrosis of the intestines, vaginal cornification, eosinophilia, sexual dysfunction, diaphoresis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160123\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to digoxin, other forms of digitalis, or any component of the formulation; ventricular fibrillation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160105\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Digoxin toxicity: Signs and symptoms of digoxin toxicity include anorexia, nausea, vomiting, visual changes, and cardiac arrhythmias; toxicity is usually associated with digoxin levels &gt;2 ng/mL, although symptoms may occur at lower levels. Patients at increased risk for digoxin toxicity include those with low body weight, advanced age, renal impairment, hypokalemia, hypercalcemia, or hypomagnesemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extravasation: IV administration: Vesicant; ensure proper needle or catheter placement prior to and during administration; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Proarrhythmic effects: Monitor for proarrhythmic effects (especially with digoxin toxicity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Accessory bypass tract (eg, Wolff-Parkinson-White [WPW] syndrome): During an episode of atrial fibrillation or flutter in patients with an accessory bypass tract or pre-excitation syndrome, use has been associated with increased anterograde conduction down the accessory pathway leading to ventricular fibrillation; avoid use in such patients (ACLS [Neumar 2010]; AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acute coronary syndrome: Use with caution in patients with an acute MI; may increase myocardial oxygen demand and lead to ischemia. During an acute coronary syndrome, digoxin administered IV may be used to slow a rapid ventricular response and improve left ventricular (LV) function in the acute treatment of atrial fibrillation associated with severe LV function and heart failure or hemodynamic instability (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Atrial fibrillation: When used for rate control in patients with atrial fibrillation, monitor serum concentrations closely; may be associated with an increased risk of mortality especially when serum concentrations are not properly controlled (Vamos 2015). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Beri beri heart disease: Patients with beri beri heart disease may fail to adequately respond to digoxin therapy; treat underlying thiamine deficiency concomitantly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy; toxicity may occur despite therapeutic digoxin concentrations (eg, &lt;2 ng/mL). Hypercalcemia may increase the risk of digoxin toxicity and hypocalcemia can nullify the effects of digoxin; maintain normocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heart failure: Digoxin should be considered for use only in heart failure (HF) with reduced ejection fraction (HFrEF) when symptoms remain despite guideline-directed medical therapy. It may also be considered in patients with both HF and atrial fibrillation; however, beta blockers may offer better ventricular rate control than digoxin (ACCF/AHA [Yancy 2013]). Withdrawal of digoxin in clinically stable patients with HF may lead to recurrence of HF symptoms (Packer 1993). Monitor serum concentrations closely; may be associated with an increased risk of mortality especially when serum concentrations are not properly controlled (Vamos 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypermetabolic states: Atrial arrhythmias associated with hypermetabolic (eg, hyperthyroidism) or hyperdynamic (hypoxia, arteriovenous shunt) states are very difficult to treat; treat underlying condition first. If digoxin is used, ensure digoxin toxicity does not occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Outflow obstruction may worsen due to the positive inotropic effects of digoxin; avoid use unless used to control ventricular response with atrial fibrillation. Digoxin is potentially harmful in the treatment of dyspnea in patients with HCM in the absence of atrial fibrillation (Gersh 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myocarditis: In a murine model of viral myocarditis, digoxin in high doses was shown to be detrimental (Matsumori 1999). If used in humans, therefore, digoxin should be used with caution and only at low doses (Frishman 2007). The manufacturer recommends avoiding the use of digoxin in patients with myocarditis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Preserved left ventricular function: Decreased cardiac output may occur in patients with preserved left ventricular systolic function, including restrictive or hypertrophic cardiomyopathy, constrictive pericarditis, amyloid heart disease, and acute cor pulmonale; in general, the manufacturer recommends to avoid use unless used to control ventricular response with atrial fibrillation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment needed. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sinus node disease and atrioventricular (AV) block: Because digoxin slows sinoatrial and AV conduction, the drug commonly prolongs the PR interval. Digoxin may cause severe sinus bradycardia or sinoatrial block particularly in patients with preexisting sinus node disease. Avoid use in patients with second- or third-degree heart block (except in patients with a functioning artificial pacemaker) (Yancy 2013); incomplete AV block (eg, Stokes-Adams attacks) may progress to complete block with digoxin administration. In such patients, if treatment with digoxin is necessary, consider the insertion of a pacemaker before treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid disease: Use with caution in patients with hypothyroidism, higher digoxin concentrations may result due to significant reduction in digoxin clearance (Burk 2010). In patients with hyperthyroidism, lower digoxin concentrations may result due to an  increase in renal clearance of digoxin. No significant differences in absorption were seen in either thyroid condition compared with those with normal thyroid function (Burk 2010). <b>Note:</b> New-onset atrial fibrillation or exacerbation of ventricular arrhythmias should prompt evaluation of thyroid status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infants: Newborn infants display considerable variability to their tolerance to digoxin; premature and immature infants are particularly sensitive to the effects of digoxin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Low body weight: Patients with decreased body weight are at an increased risk of drug-related toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elective electrical cardioversion: It is not necessary to routinely reduce or hold digoxin therapy prior to elective electrical cardioversion for atrial fibrillation; however, exclusion of digoxin toxicity (eg, clinical and ECG signs) is necessary prior to cardioversion. If signs of digoxin excess exist, withhold digoxin and delay cardioversion until toxicity subsides (AHA/ACC/HRS [January 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160185\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160110\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9360&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: May decrease the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acarbose: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adenosine: Digoxin may enhance the adverse/toxic effect of Adenosine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.<b> Exceptions: </b>Amikacin; Kanamycin; Streptomycin; Tobramycin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoquinolines (Antimalarial): May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May increase the serum concentration of Cardiac Glycosides. Management: Reduce the dose of cardiac glycosides by 30% to 50%  or reduce the frequency of administration when initiating concomitant amiodarone therapy. Monitor for increased serum concentrations and toxic effects  of cardiac glycosides.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the adverse/toxic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anagliptin: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anthracyclines: Cardiac Glycosides may diminish the cardiotoxic effect of Anthracyclines. Anthracyclines may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithyroid Agents: May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barnidipine: May enhance the adverse/toxic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benidipine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the bradycardic effect of Cardiac Glycosides.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Cardiac Glycosides.<b> Exceptions: </b>Colesevelam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Digoxin. Management: In patients initiating digoxin during boceprevir treatment, initiate at the lowest possible digoxin dose, monitor serum digoxin concentrations, and titrate carefully due to a possible risk of elevated digoxin concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the bradycardic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: Digoxin may enhance the bradycardic effect of Carvedilol. Carvedilol may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloNIDine: May enhance the AV-blocking effect of Cardiac Glycosides. Sinus node dysfunction may also be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: Digoxin may increase the serum concentration of Colchicine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: May increase the serum concentration of Digoxin. Management: See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diacerein: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: Digoxin may enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin.  Management: Avoid concurrent use of digoxin when possible.  If concurrent use is necessary, reduce adult digoxin dose by 50%,  monitor digoxin concentration closely, and increase monitoring for both clinical response to therapy and the occurrence of adverse effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edrophonium: May enhance the AV-blocking effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: May increase the serum concentration of Digoxin. Management: In patients receiving digoxin, measure digoxin serum concentrations prior to initiating eliglustat.  Preemptively reduce digoxin doses by 30% and continue monitoring following eliglustat initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Nasal): Cardiac Glycosides may enhance the arrhythmogenic effect of EPHEDrine (Nasal). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Systemic): May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epoprostenol: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May increase the serum concentration of Digoxin. Management: Monitor serum digoxin concentrations and adjust dose as needed. In patients initiating a regimen of digoxin with etravirine, digoxin should be initiated at the lowest dose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: May increase the serum concentration of Digoxin. Management: Measure serum digoxin concentrations before initiating glecaprevir/pibrentasvir. Reduce digoxin concentrations by decreasing the digoxin dose by approximately 50% or by modifying the dosing frequency; continue monitoring during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Systemic): May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Cardiac Glycosides. Management: Consider preemptive cardiac glycoside dose adjustments with initiation / changes / discontinuation of itraconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kaolin: May decrease the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: May enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, levosulpiride may diminish symptoms of cardiac glycoside-related toxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Licorice: May enhance the adverse/toxic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of loop diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Cardiac Glycosides.<b> Exceptions: </b>Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaraminol: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midodrine: Cardiac Glycosides may enhance the bradycardic effect of Midodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of Digoxin. Management: Measure serum digoxin concentration 1-2 weeks following mifepristone initiation, and in accordance with normal clinical practice thereafter, adjusting dose as needed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Milnacipran: May enhance the adverse/toxic effect of Digoxin. The risk of postural hypotension and tachycardia may be increased, particularly with IV digoxin. Management: Avoid concurrent use of intravenous (IV) digoxin in patients receiving milnacipran. Use caution when using oral digoxin and milnacipran together, monitoring closely for possible postural hypotension and tachycardia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: May increase the serum concentration of Digoxin. Management: Consider using the lowest dose of digoxin when initiating concurrent mirabegron.  Monitor serum digoxin concentrations closely to help guide digoxin dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nefazodone: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of Digoxin. Management: When initiating the ombitasvir/paritaprevir/ritonavir combination product in patients taking digoxin, decrease the digoxin dose by 30% to 50% and monitor serum digoxin levels to determine further dose adjustments.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parathyroid Hormone: May enhance the adverse/toxic effect of Cardiac Glycosides. More specifically, Parathyroid Hormone-related hypercalcemia may predispose to digitalis toxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paricalcitol: May enhance the adverse/toxic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PenicillAMINE: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polyethylene Glycol 3350: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polyethylene Glycol 4000: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: May diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May increase the serum concentration of Cardiac Glycosides. Management: Upon quinidine initiation, consider reducing cardiac glycoside dose by 25% to 50%, with continued monitoring of glycoside serum concentrations and clinical response until the quinidine reaches steady state (5-10 days).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: May enhance the adverse/toxic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Digoxin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roxithromycin: May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SITagliptin: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasing Digoxin concentrations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the serum concentration of Digoxin. Specifically, sucralfate may decrease the absorption of digoxin. Management: Administer digoxin at least 2 hours before or at least 6 hours after sucralfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Digoxin. Management: Use the lowest possible digoxin dose when starting therapy in a patient who is being treated with telaprevir, and monitor clinical response and serum concentrations closely for further dosing adjustments.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telmisartan: May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of thiazide diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valbenazine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vandetanib: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of Digoxin. Management: Avoid coadministration of vemurafenib and digoxin when possible.  If concomitant use cannot be avoided, consider digoxin dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May increase the serum concentration of Digoxin. Management: Administer digoxin at least 6 hours before venetoclax when concomitant therapy is required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160139\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Digoxin peak serum concentrations may be decreased if taken with food. Meals containing increased fiber (bran) or foods high in pectin may decrease oral absorption of digoxin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160112\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9729170\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Digoxin crosses the placenta and serum concentrations are similar in the mother and fetus at delivery. Digoxin is recommended in the treatment of fetal tachycardia determined to be SVT. In pregnant women, use of digoxin is recommended as a first-line agent for chronic treatment of highly symptomatic SVT; the lowest effective dose is recommended (Page [ACC/AHA/HRS 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9729172\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Digoxin is excreted into breast milk and similar concentrations are found within mother's serum and milk (milk/plasma ratio ~0.6 to 0.9). However, this exposure is expected to be less than the usual therapeutic infant dose and adverse events to a nursing infant are not expected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160126\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Maintain adequate amounts of potassium in diet to decrease risk of hypokalemia (hypokalemia may increase risk of digoxin toxicity).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160114\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Heart rate and rhythm should be monitored along with periodic ECGs to assess desired effects and signs of toxicity; baseline and periodic serum creatinine. Periodically monitor serum potassium, magnesium, and calcium especially if on medications where these electrolyte disturbances can occur (eg, diuretics), or if patient has a history of hypokalemia or hypomagnesemia. Observe patients for noncardiac signs of toxicity, confusion, and depression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">When to draw serum digoxin concentrations: Digoxin serum concentrations are monitored because digoxin possesses a narrow therapeutic serum range; the therapeutic endpoint is difficult to quantify and digoxin toxicity may be life-threatening. Digoxin serum concentrations should be drawn <b>at least 6 to 8 hours after last dose, regardless of route of administration (optimally 12 to 24 hours after a dose). Note:</b> Serum digoxin concentrations may decrease in response to exercise due to increased skeletal muscle uptake; a period of rest (eg, ~2 hours) after exercise may be necessary prior to drawing serum digoxin concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Initiation of therapy: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>If a loading dose is given:</b> Digoxin serum concentration may be drawn within 12 to 24 hours after the initial loading dose administration. Concentrations drawn this early may confirm the relationship of digoxin plasma concentrations and response but are of little value in determining maintenance doses. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>If a loading dose is not given:</b> Digoxin serum concentration should be obtained after 3 to 5 days of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Maintenance therapy: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Trough</b> concentrations should be followed just prior to the next dose or at a minimum of 6 to 8 hours after last dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Digoxin serum concentrations should be obtained within 5 to 7 days (approximate time to steady-state) after any dosage changes. Continue to obtain digoxin serum concentrations 7 to 14 days after any change in maintenance dose. <b>Note:</b> In patients with end-stage renal disease, it may take 15 to 20 days to reach steady-state. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Patients who are receiving electrolyte-depleting medications such as diuretics, serum potassium, magnesium, and calcium should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Digoxin serum concentrations should be obtained whenever any of the following conditions occur: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Questionable patient compliance or to evaluate clinical deterioration following an initial good response </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Changing renal function </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Suspected digoxin toxicity </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Initiation or discontinuation of therapy with drugs (eg, amiodarone, quinidine, verapamil) which potentially interact with digoxin.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Any disease changes (eg, thyroid disease) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160117\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Digoxin therapeutic serum concentrations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Heart failure: 0.5 to 0.9 ng/mL (SI: 0.6 to 1.2 nmol/L) (ACCF/AHA [Yancy 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adults: 0.8 to 2.0 ng/mL (SI: 1.0 to 2.6 nmol/L); &lt;0.5 ng/mL (SI: &lt;0.6 nmol/L) probably indicates underdigitalization unless there are special circumstances</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Toxic: &gt;2 ng/mL (&gt;2.6 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin-like immunoreactive substance (DLIS) may cross-react with digoxin immunoassay. DLIS has been found in patients with renal and liver disease, heart failure, neonates, and pregnant women (3rd trimester).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160104\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heart failure: Inhibition of the sodium/potassium ATPase pump in myocardial cells results in a transient increase of  intracellular sodium, which in turn promotes calcium influx via the sodium-calcium exchange pump leading to increased contractility. May improve baroreflex sensitivity (Gheorghiade 1991).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Supraventricular arrhythmias: Direct suppression of the AV node conduction to increase effective refractory period and decrease conduction velocity - positive inotropic effect, enhanced vagal tone, and decreased ventricular rate to fast atrial arrhythmias. Atrial fibrillation may decrease sensitivity and increase tolerance to higher serum digoxin concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160122\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Heart rate control: Oral: 1 to 2 hours; IV: 5 to 60 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Heart rate control: Oral: 2 to 8 hours; IV: 1 to 6 hours; <b>Note:</b> In patients with atrial fibrillation, median time to ventricular rate control in one study was 6 hours (range: 3 to 15 hours) (Siu, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Adults: 3 to 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: By passive nonsaturable diffusion in the upper small intestine; food may delay, but does not affect extent of absorption </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Normal renal function: 6 to 7 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: Extensive to peripheral tissues, with a distinct distribution phase which lasts 6 to 8 hours; concentrates in heart, liver, kidney, skeletal muscle, and intestines. Heart/serum concentration is 70:1. Pharmacologic effects are delayed and do not correlate well with serum concentrations during distribution phase. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hyperthyroidism: Increased V<sub>d</sub></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hyperkalemia, hyponatremia: Decreased digoxin distribution to heart and muscle </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypokalemia: Increased digoxin distribution to heart and muscles </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Concomitant quinidine therapy: Decreased V<sub>d</sub></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chronic renal failure: 4 to 6 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decreased sodium/potassium ATPase activity - decreased tissue binding </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates, full-term: 7.5 to 10 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 16 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 7 L/kg, decreased with renal disease </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~25%; in uremic patients, digoxin is displaced from plasma protein binding sites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Via sequential sugar hydrolysis in the stomach or by reduction of lactone ring by intestinal bacteria (in ~10% of population, gut bacteria may metabolize up to 40% of digoxin dose); once absorbed, only ~16% is metabolized to 3-beta-digoxigenin, 3-keto-digoxigenin, and glucuronide and sulfate conjugates; metabolites may contribute to therapeutic and toxic effects of digoxin; metabolism is reduced with decompensated HF</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral (formulation dependent): Elixir: 70% to 85%; Tablet: 60% to 80% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination (age, renal and cardiac function dependent): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: Premature: 61 to 170 hours; Full-term: 35 to 45 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: 18 to 25 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 18 to 36 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 36 to 48 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults, anephric: 3.5 to 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Parent drug: 38 hours; Metabolites: Digoxigenin: 4 hours; Monodigitoxoside: 3 to 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 1 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (50% to 70% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160125\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Digoxin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/mL (2 mL): $7.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Digoxin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/mL (60 mL): $168.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lanoxin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/mL (2 mL): $101.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lanoxin Pediatric Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/mL (1 mL): $101.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Digitek Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (100): $230.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (100): $230.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Digox Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (100): $230.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (100): $230.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Digoxin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (100): $210.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (100): $207.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Lanoxin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">62.5 mcg (100): $1,490.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (100): $1,490.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">187.5 mcg (100): $1,490.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (100): $1,490.83</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160127\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agoxin (BD);</li>\n      <li>Cadef Elixir Pediatric (KR);</li>\n      <li>Cardcor (BR, LI);</li>\n      <li>Cardiacin (TW);</li>\n      <li>Cardigo (LK);</li>\n      <li>Cardiogoxin (AR);</li>\n      <li>Cardioxin (PH);</li>\n      <li>Cardoxin (IL);</li>\n      <li>Centoxin (BD);</li>\n      <li>Digosin (JP, KR);</li>\n      <li>Digox (PH);</li>\n      <li>Digoxicor (LV);</li>\n      <li>Digoxil (PY);</li>\n      <li>Digoxin (PL);</li>\n      <li>Digoxin NI (ID);</li>\n      <li>Digoxin &rdquo;Dak&rdquo; (DK);</li>\n      <li>Digoxin-Actavis (HK);</li>\n      <li>Digoxin-Sandoz (BF, BJ, CH, CI, ET, GH, GM, GN, ID, JP, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Digoxin-Zori (IL);</li>\n      <li>Digoxina (CO, ES, GT, HN, NI, PE);</li>\n      <li>Digoxine Nativelle (LU);</li>\n      <li>Digoxine Navtivelle (FR);</li>\n      <li>Dilacor (BG);</li>\n      <li>Dilanacin (CY, EG, IQ, SD);</li>\n      <li>Dixcool (LK);</li>\n      <li>Eudigox (IT);</li>\n      <li>Fargoxin (ID);</li>\n      <li>Grekin (LI);</li>\n      <li>Grexin (TH);</li>\n      <li>Ke Li (CN);</li>\n      <li>Lanacordin (ES);</li>\n      <li>Lanibos (KW, SA);</li>\n      <li>Lanicor (AR, AT, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, CZ, DE, EC, EG, ET, GH, GM, GN, GR, GY, HR, IQ, IR, JM, KE, LI, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, OM, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, VE, YE, ZM, ZW);</li>\n      <li>Lanikor (RU);</li>\n      <li>Lanioxin (IS);</li>\n      <li>Lanitop (SA);</li>\n      <li>Lanoxin (AE, AR, AU, BB, BD, BE, BF, BH, BJ, BM, BS, BZ, CI, CR, CY, DO, EG, ET, GB, GH, GM, GN, GR, GT, GY, HK, HN, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KE, KR, KW, LB, LI, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PH, PK, PT, PY, QA, RU, SA, SC, SD, SE, SG, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, YE, ZM, ZW);</li>\n      <li>Lanoxin PG (NZ, QA);</li>\n      <li>Lenoxin (DE);</li>\n      <li>Mapluxin (MX);</li>\n      <li>Myoxin (BD);</li>\n      <li>Purgoxin (ZA);</li>\n      <li>Sigmaxin (AU);</li>\n      <li>Toloxin (TH);</li>\n      <li>Valvulan (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vidaxil (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults [published online October 8, 2015]. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 42.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1403399\"></a>Azancot-Benisty A, Jacqz-Aigrain E, Guirgis NM, Decrepy A, Oury JF, Blot P. Clinical and pharmacologic study of fetal supraventricular tachyarrhythmias. <i>J Pediatr</i>. 1992;121(4):608-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/1403399/pubmed\" target=\"_blank\" id=\"1403399\">1403399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauman JL, DiDomenico RJ, Viana M, et al,&rdquo; A Method of Determining the Dose of Digoxin for Heart Failure in the Modern Era,&rdquo; <i>Arch Intern Med</i>, 2006,166(22):2539-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/17159022/pubmed\" target=\"_blank\" id=\"17159022\">17159022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burk O, Brenner SS, Hofmann U, et al. The Impact of Thyroid Disease on the regulation, expression, and function of ABCB1 (MDRa/P-glycoprotein) and consequences for the disposition of digoxin. <i>Clin Pharm Ther</i>. 2010;88(5):685-694.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/20844484/pubmed\" target=\"_blank\" id=\"20844484\">20844484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheng JW and Rybak I, &ldquo;Use of Digoxin for Heart Failure and Atrial Fibrillation in Elderly Patients,&rdquo; <i>Am J Geriatr Pharmacother</i>, 2010, 8(5):419-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/21335295/pubmed\" target=\"_blank\" id=\"21335295\">21335295</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Digitek (digoxin) tablets [prescribing information]. Morgantown, WV: Mylan; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Falk RH, Knowlton AA, Bernard SA, et al, &ldquo;Digoxin for Converting Recent-Onset Atrial Fibrillation to Sinus Rhythm, A Randomized, Double-Blinded Trial,&rdquo; <i>Ann Int Med</i>, 1987, 106(4):503-6<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/3548521/pubmed\" target=\"_blank\" id=\"3548521\">3548521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frishman WH, Zeidner J, Naseer N. Diagnosis and Management of Viral Myocarditis. <i>Curr Treat Options Cardiovas Med</i>. 2007;9:450-464.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/18221597/pubmed\" target=\"_blank\" id=\"18221597\">18221597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124(24):e783-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/22068434/pubmed\" target=\"_blank\" id=\"22068434\">22068434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gheorghiade M and Ferguson D. Digoxin. A neurohormonal modulator in heart failure? <i>Circulation</i>. 1991;84(5):2181-2186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/1834367/pubmed\" target=\"_blank\" id=\"1834367\">1834367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golightly LK, Teitelbaum I, Kiser TH, et al. (eds.) <i>Renal Pharmacotherapy</i>. Springer Science, New York. 2013</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(23):2610-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Intravenous Digoxin in Acute Atrial Fibrillation. Results of a Randomized, Placebo-Controlled Multicentre Trial in 239 Patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group,&rdquo; <i>Eur Heart J</i>, 1997, 18(4):649-54<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/9129897/pubmed\" target=\"_blank\" id=\"9129897\">9129897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21931080\"></a>Jaeggi ET, Carvalho JS, De Groot E, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. <i>Circulation</i>. 2011;124(16):1747-1754.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/21931080/pubmed\" target=\"_blank\" id=\"21931080\">21931080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>. doi:10.1161/CIR.0000000000000041.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span><span class=\"doi\">10.1161/CIR.0000000000000041</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jordaens L, Trouerbach J, Calle P, et al, &ldquo;Conversion of Atrial Fibrillation to Sinus Rhythm and Rate Control by Digoxin in Comparison to Placebo,&rdquo; <i>Eur Heart J</i>, 1997, 18(4):643-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/9129896/pubmed\" target=\"_blank\" id=\"9129896\">9129896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jusko WJ, Szefler SJ, and Goldfarb AL, &ldquo;Pharmacokinetic Design of Digoxin Dosage Regimens in Relation to Renal Function,&rdquo; <i>J Clin Pharmacol</i>, 1974, 14(10):525-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/4430731/pubmed\" target=\"_blank\" id=\"4430731\">4430731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koup JR, Jusko WJ, Elwood CM, et al, &ldquo;Digoxin Pharmacokinetics: Role of Renal Failure in Dosage Regimen Design,&rdquo; <i>Clin Pharmacol Ther</i>, 1975, 18(1):9-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/1149366/pubmed\" target=\"_blank\" id=\"1149366\">1149366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lanoxin (digoxin) tablets [prescribing information]. Research Triangle Park, NC: Glaxosmithkline; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lanoxin (digoxin) injection [prescribing information]. Cary, NC: Covis Pharmaceuticals Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lanoxin (digoxin) tablets [product monograph]. Montreal, Quebec, Canada: Pharmascience; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo; <i>J Card Fail</i>, 2010, 16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matsumori A, Igata H, Ono K, et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. <i>Jpn Circ J</i>. 1999;63:934-990.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/10614837/pubmed\" target=\"_blank\" id=\"10614837\">10614837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murgatroyd FD, Gibson SM, Baiyan X, et al, &ldquo;Double-Blind Placebo-Controlled Trial of Digoxin in Symptomatic Paroxysmal Atrial Fibrillation,&rdquo; <i>Circulation</i>, 1999, 99(21):2765-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/10351970/pubmed\" target=\"_blank\" id=\"10351970\">10351970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2011;123(6):e236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Packer M, Gheorghiade M, Young JB, et al, &ldquo;Withdrawal of Digoxin From Patients With Chronic Heart Failure Treated With Angiotensin-converting Enzyme Inhibitors, RADIANCE Study,&rdquo; <i>N Engl J Med</i>, 1993, 329(1):1-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/8505940/pubmed\" target=\"_blank\" id=\"8505940\">8505940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115. doi: 10.1016/j.jacc.2015.08.856.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/26409259/pubmed\" target=\"_blank\" id=\"26409259\">26409259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rathore SS, Curtis JP, Wang Y, et al, &ldquo;Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure,&rdquo; <i>JAMA</i>, 2003, 289(7):871-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/12588271/pubmed\" target=\"_blank\" id=\"12588271\">12588271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts SA, Diaz C, Nolan PE, et al, &ldquo;Effectiveness and Costs of Digoxin Treatment for Atrial Fibrillation and Flutter,&rdquo; <i>Am J Cardiol</i>, 1993, 72(7):567-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/8362772/pubmed\" target=\"_blank\" id=\"8362772\">8362772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenthal D, Chrisant MR, Edens E, et al, &ldquo;International Society for Heart and Lung Transplantation: Practice Guidelines for Management of Heart Failure in Children,&rdquo; <i>J Heart Lung Transplant</i>, 2004, 23(12):1313-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/15607659/pubmed\" target=\"_blank\" id=\"15607659\">15607659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siu CW, Lau CP, Lee WL, et al, &ldquo;Intravenous Diltiazem is Superior to Intravenous Amiodarone or Digoxin for Achieving Ventricular Rate Control in Patients With Acute Uncomplicated Atrial Fibrillation,&rdquo; <i>Crit Care Med</i>, 2009, 37(7):2174-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/19487941/pubmed\" target=\"_blank\" id=\"19487941\">19487941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo; <i>Can J Cardiol</i>, 2012, 28(2):125-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/22433576/pubmed\" target=\"_blank\" id=\"22433576\">22433576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;The Effect of Digoxin on Mortality and Morbidity in Patients With Heart Failure. The Digitalis Investigation Group,&rdquo; <i>N Engl J Med</i>, 1997, 336(8):525-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/9036306/pubmed\" target=\"_blank\" id=\"9036306\">9036306</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ujhelyi MR and Robert S, &ldquo;Pharmacokinetic Aspects of Digoxin-Specific Fab Therapy in the Management of Digitalis Toxicity,&rdquo; <i>Clin Pharmacokinet</i>, 1995, 28(6):483-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/7656506/pubmed\" target=\"_blank\" id=\"7656506\">7656506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. <i>Eur Heart J</i>. 2015 May 4. pii: ehv143. [Epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/25939649/pubmed\" target=\"_blank\" id=\"25939649\">25939649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7930263\"></a>van Engelen AD, Weijtens O, Brenner JI, et al. Management outcome and follow-up of fetal tachycardia. <i>J Am Coll Cardiol</i>. 1994;24(5):1371-1375.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/7930263/pubmed\" target=\"_blank\" id=\"7930263\">7930263</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9360 Version 263.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F160142\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F160143\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F160189\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F160147\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F160169\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F160148\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F160149\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15796078\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F160116\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F160101\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950035\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F803126\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F160120\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725522\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F160198\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F160108\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F160123\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F160105\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F160185\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F160110\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F160139\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F160112\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9729170\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9729172\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F160126\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F160114\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F160117\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F160104\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F160122\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F160125\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F160127\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9360|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=digoxin-patient-drug-information\" class=\"drug drug_patient\">Digoxin: Patient drug information</a></li><li><a href=\"topic.htm?path=digoxin-pediatric-drug-information\" class=\"drug drug_pediatric\">Digoxin: Pediatric drug information</a></li></ul></div></div>","javascript":null}